A Safety and Tolerability Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus

General Information

Summary The purpose of this trial is to test if VC-02™ combination product can be implanted subcutaneously in subjects with Type 1 Diabetes and maintained safely for up to four (4) months.
Description Not Provided
Clinical trials phase Phase 1
Start date (estimated) 2017-07-05
End date (estimated) 2018-02-15
Clinical feature
Label type 1 diabetes mellitus
Link http://purl.obolibrary.org/obo/DOID_9744
Description A diabetes mellitus that is characterized by destruction of pancreatic beta cells resulting in absent or extremely low insulin production.; Xref MGI. OMIM mapping confirmed by DO. [SN].

Administrative Information

NCT number NCT03162926
ICTRP weblink https://trialsearch.who.int/Trial2.aspx?TrialID=NCT03162926
Other study identifiers
Name VC02-102
Source weblink https://clinicaltrials.gov/ct2/show/study/NCT03162926
Regulatory body approval
Name Food and Drug Administration (FDA)
United States
Public contact
Email info@viacyte.com
Public email info@viacyte.com
United States
Sponsors ViaCyte


Source pluripotent stem cell lines
Which differentiated cell type is used
Label progenitor cell of endocrine pancreas
Link http://purl.obolibrary.org/obo/CL_0002351
Description A progenitor cell that is able to differentiate into the pancreas alpha, beta and delta endocrine cells. This cell type expresses neurogenin-3 and Isl-1.


Recruitment Status Completed
Estimated number of participants 3